Akeso (SHSC:9926) - Cours de l'action, nouvelles et analyse

9926 Aperçu des actions

Akeso, Inc. est une société biopharmaceutique qui recherche, développe, fabrique et commercialise des médicaments à base d'anticorps. Plus de détails

9926 analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	6/6
Performances passées	0/6
Santé financière	4/6
Dividendes	0/6

Récompenses

Se négocie à 44.7% en dessous de notre estimation de sa juste valeur

Les bénéfices devraient augmenter 53.31% par an

Analyse des risques

Les actionnaires ont été dilués au cours de l'année écoulée

Akeso, Inc. Concurrents

Innovent Biologics

SEHK:1801

HK$60.6b

Ascentage Pharma Group International

SEHK:6855

HK$12.7b

Shanghai Henlius Biotech

SEHK:2696

HK$11.0b

Sichuan Kelun-Biotech Biopharmaceutical

SEHK:6990

HK$37.4b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Akeso
Historique des cours de bourse
Prix actuel de l'action	HK$72.20
Plus haut sur 52 semaines	HK$77.65
Plus bas sur 52 semaines	HK$26.45
Bêta	0.56
1Variation sur 1 mois	4.18%
Variation sur 3 mois	57.30%
Variation sur 1 an	54.11%
3Variation sur 3 ans	49.79%
Variation sur 5 ans	n/a
Évolution depuis l'introduction en bourse	91.26%

Nouvelles et mises à jour récentes

Recent updates

Rendement pour les actionnaires

	9926	HK Biotechs	HK Marché
7D	5.0%	2.2%	1.6%
1Y	54.1%	-13.1%	10.1%

Rendement vs Industrie: 9926 a dépassé le secteur Hong Kong Biotechs qui a rapporté -13.1 % au cours de l'année écoulée.

Rendement vs marché: 9926 a dépassé le marché Hong Kong qui a rapporté 10.1 % au cours de l'année écoulée.

Volatilité des prix

Is 9926's price volatile compared to industry and market?
9926 volatility
9926 Average Weekly Movement	10.9%
Biotechs Industry Average Movement	10.9%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	19.0%
10% least volatile stocks in HK Market	4.3%

Cours de l'action stable: 9926 n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de 9926 ( 11% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2012	2,815	Michelle Xia	www.akesobio.com

Akeso, Inc. est une société biopharmaceutique qui recherche, développe, fabrique et commercialise des médicaments à base d'anticorps. La société développe l'AK104, un anticorps bi-spécifique PD-1/CTLA-4 pour traiter le cancer du col de l'utérus, le cancer gastrique (GC), le cancer de la jonction gastro-œsophagienne (GEJ), l'ESCC, le carcinome hépatocellulaire (HCC), le cancer du poumon à petites cellules (SCLC), le cancer du poumon non à petites cellules (NSCLC), le cancer du pancréas, et les tumeurs solides ; et l'AK112, un anticorps bi-spécifique PD-1/VEGF pour traiter le NSCLC, le cancer du sein triple négatif (TNBC), le cancer de la tête et du cou, le HCC, le cancer colorectal, le cancer de l'ovaire et les tumeurs solides. Elle développe également l'AK117, un anticorps monoclonal CD47 pour traiter le syndrome myélodysplasique, la leucémie myéloïde aiguë, le GC, le GEJ, l'ESCC, le HNSCC, le CRC, le TNBC et les tumeurs solides/lymphomes ; AK105, un anticorps monoclonal PD-1 pour traiter le lymphome de Hodgkin classique (R/R cHL), NSCLC, NPC, HCC, SCLC, cancer de la thyroïde, mésothéliome et cancer du thymus, ESCC, UC, GC, GEJ, cholangiocarcinome, tumeur neuroendocrine, et tumeur solide déficiente dans la réparation des mésappariements ; AK119, un anticorps monoclonal CD73 pour le traitement des tumeurs solides et du NSCLC ; et AK109, un anticorps monoclonal VEGFR-2 pour le traitement du GC, du GEJ, du NSCLC, du HCC et des tumeurs solides.

Akeso, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Akeso se comparent-ils à sa capitalisation boursière ?
9926 statistiques fondamentales
Capitalisation boursière	HK$64.80b
Bénéfices(TTM)	-HK$789.78m
Recettes(TTM)	HK$2.01b

32.2x

Ratio P/S

-82.1x

Ratio P/E

Le site 9926 est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
9926 compte de résultat (TTM)
Recettes	CN¥1.87b
Coût des recettes	CN¥146.05m
Marge brute	CN¥1.73b
Autres dépenses	CN¥2.46b
Les revenus	-CN¥735.33m

Derniers bénéfices déclarés

Jun 30, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-0.82
Marge brute	92.21%
Marge bénéficiaire nette	-39.24%
Ratio dettes/capitaux propres	64.2%

Quelles ont été les performances à long terme de 9926?

Voir les performances historiques et les comparaisons

9926 Aperçu des actions

Récompenses

Analyse des risques

Akeso, Inc. Concurrents

SEHK:1801

HK$60.6b

SEHK:6855

HK$12.7b

SEHK:2696

HK$11.0b

SEHK:6990

HK$37.4b

Historique des prix et performances

Nouvelles et mises à jour récentes

Akeso, Inc.'s Penpulimab Combination Therapy for First-Line Treatment of Hepatocellular Carcinoma Accepted by NMPA

Akeso, Inc. Publishes Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting

Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.942576 billion.

Akeso Biopharma Announces Positive Results in Progression-Free Survival (PFS) and Overall Survival (OS) from Its Phase 3 Clinical Study

First half 2024 earnings released: CN¥0.28 loss per share (vs CN¥3.02 profit in 1H 2023)

Recent updates

Akeso, Inc.'s Penpulimab Combination Therapy for First-Line Treatment of Hepatocellular Carcinoma Accepted by NMPA

Akeso, Inc. Publishes Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting

Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.942576 billion.

Akeso Biopharma Announces Positive Results in Progression-Free Survival (PFS) and Overall Survival (OS) from Its Phase 3 Clinical Study

First half 2024 earnings released: CN¥0.28 loss per share (vs CN¥3.02 profit in 1H 2023)

Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population

Akeso, Inc. Secures Approval from China’s National Medical Products Administration for Ebronucimab, Expanding Treatment Options for Hypercholesterolemia

Akeso's Ivonescimab Plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety At ESMO 2024

First half 2024 earnings released: CN¥0.28 loss per share (vs CN¥3.02 profit in 1H 2023)

Akeso, Inc. to Report Q2, 2024 Results on Aug 28, 2024

Akeso, Inc. Announces Ivonescimab (Pd-1/Vegf) Received Priority Review from China's Nmpa for First-Line Treatment of Pd-L1 Positive Nsclc

Akeso, Inc. Announces That the First Patient Enrolled in the US Phase 2 Combination Therapy of it's Ligufalimab with Azacitidine for Myelodysplastic Syndrome

Akeso's Sbla for Ivonescimab in 1L Treatment of Pd-L1 Positive Nsclc Accepted by NMPA

Akeso, Inc. Announces Appointment of Bing C. Wang as Chief Financial Officer

New major risk - Share price stability

Akeso, Inc. Announces Change of Directors

Akeso, Inc. Announces Change of Directors

Akeso, Inc., Annual General Meeting, Jun 30, 2024

Akeso, Inc. Announces Phase III Clinical Trial, Harmoni-2 or AK112-303 Met Its Primary Endpoint of Progression-Free Survival

New minor risk - Share price stability

Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection

Investor sentiment deteriorates as stock falls 24%

Full year 2023 earnings released: EPS: CN¥2.42 (vs CN¥1.42 loss in FY 2022)

National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Full year 2023 earnings released: EPS: CN¥2.42 (vs CN¥1.42 loss in FY 2022)

Investor sentiment improves as stock rises 15%

Akeso, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC

Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI

Akeso, Inc. Announces Innovative Clinical Development Roadmap

Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer

Akeso, Inc. Publishes Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-nave Acute Myeloid Leukemia at ASH 2023

Akeso Publishes Results from Three Investigator-Initiated Trials

Founder recently sold HK$96m worth of stock

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso, Inc. Announces AK104-303, A Phase III Trial of Cadonilimab Reached Progression-Free-Survival Primary Endpoint At Interim Analysis for First Line Treatment of Cervical Cancer

Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)

Co-Founder recently sold HK$4.4m worth of stock

Investor sentiment improves as stock rises 17%

Akeso Announces Results of Phase Ib Clinical Trial for PD-1/VEGF Bispecific Antibody

Akeso Announces the Publication of the Phase 1a/1b First-In-Human Study

Akeso, Inc. Announces Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)

Akeso, Inc. Announces FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes

First half 2023 earnings released: EPS: CN¥3.02 (vs CN¥0.77 loss in 1H 2022)

New major risk - Revenue and earnings growth

Akeso Inc. Announces Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-Line PD-L1 Positive Advanced NSCLC

Akeso, Inc. Announces the National Medical Products Administration Accepts the New Drug Application for the Ebdarokimab Injection (IL-12/IL-23 Monoclonal Antibody, AK101)

Akeso Inc. Announces First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-Line Treatment of Squamous NSCLC

Akeso, Inc. to Report First Half, 2023 Results on Aug 29, 2023

New minor risk - Share price stability

Akeso, Inc., Annual General Meeting, Jun 28, 2023

NMPA Accepts Akeso's Ebronucimab (PCSK9 ) Marketing Application in Two Cardiovascular Indications

No longer forecast to breakeven

Full year 2022 earnings released: CN¥1.42 loss per share (vs CN¥1.32 loss in FY 2021)